The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Correlation of efficacy between rash and lapatinib/capecitabine therapy in Japanese HER2-positive metastatic breast cancer patients.
S. E. Nagai
No relevant relationships to disclose
K. Inoue
No relevant relationships to disclose
S. Kaneko
No relevant relationships to disclose
S. Uchida
No relevant relationships to disclose
T. Higuchi
No relevant relationships to disclose
Y. Hayashi
No relevant relationships to disclose
T. Yoshida
No relevant relationships to disclose
H. Takei
No relevant relationships to disclose
M. Kurosumi
No relevant relationships to disclose
T. Tabei
No relevant relationships to disclose